Kathrin Meyer

Dr. Kathrin Meyer

Nationwide Children's Hospital, Columbus, Ohio, USA
+1

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 February 2016 in Nature Medicine
Verified
Journal Article
Open access
PDF file
SSSungWon Song
SungWon Song
CMCarlos J Miranda
Carlos J Miranda
LBLyndsey Braun
Lyndsey Braun
KMKathrin Meyer
Kathrin Meyer
AFAshley E Frakes
Ashley E Frakes
BKBrian K Kaspar
Brian K Kaspar
Expression of MHC class I molecules on motor neurons protects them from astrocyte-induced toxicity in ALS. Astrocytes isolated from individuals with amyotrophic lateral sclerosis (ALS) are toxic to motor neurons (MNs) and play a non–cell autonomous role in disease pathogenesis. The mechanisms underlying the susceptibility of MNs to cell death remain unclear. Here we report that astrocytes derived from either mice bearing mutations in genes associated with ALS or human subjects with ALS reduce the expression of major histocompatibility complex class I (MHCI) molecules on MNs; reduced MHCI expression makes these MNs susceptible to astrocyte-induced cell death. Increasing MHCI expression on MNs increases survival and motor performance in a mouse model of ALS and protects MNs against astrocyte toxicity. Overexpression of a single MHCI molecule, HLA-F, protects human MNs from ALS astrocyte–mediated toxicity, whereas knockdown of its receptor, the killer cell immunoglobulin-like receptor KIR3DL2, on human astrocytes results in enhanced MN death. Thus, our data indicate that, in ALS, loss of MHCI expression on MNs renders them more vulnerable to astrocyte-mediated toxicity.

5 July 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
GHGuillaume Hautbergue
Guillaume Hautbergue
LCLydia M. Castelli
Lydia M. Castelli
LFLaura Ferraiuolo
Laura Ferraiuolo
ASAlvaro Sanchez-Martinez
Alvaro Sanchez-Martinez
JCJohnathan Cooper-Knock
Johnathan Cooper-Knock
PSPamela Jean Shaw
Pamela Jean Shaw
Hexanucleotide repeat expansions in theC9ORF72gene are the commonest known genetic cause of amyotrophic lateral sclerosis and frontotemporal dementia. Expression of repeat transcripts and dipeptide repeat proteins trigger multiple mechanisms of neurotoxicity. How repeat transcripts get exported from the nucleus is unknown. Here, we show that depletion of the nuclear export adaptor SRSF1 prevents neurodegeneration and locomotor deficits in aDrosophilamodel of C9ORF72-related disease. This intervention suppresses cell death of patient-derived motor neuron and astrocytic-mediated neurotoxicity in co-culture assays. We further demonstrate that either depleting SRSF1 or preventing its interaction with NXF1 specifically inhibits the nuclear export of pathologicalC9ORF72transcripts, the production of dipeptide-repeat proteins and alleviates neurotoxicity inDrosophila, patient-derived neurons and neuronal cell models. Taken together, we show that repeat RNA-sequestration of SRSF1 triggers the NXF1-dependent nuclear export ofC9ORF72transcripts retaining expanded hexanucleotide repeats and reveal a novel promising therapeutic target for neuroprotection.

15 November 2018 in JCI Insight
Verified
Journal Article
Closed access
PDF file
CGCarlee R. Giesige
Carlee R. Giesige
LWLindsay M. Wallace
Lindsay M. Wallace
KHKristin N. Heller
Kristin N. Heller
JEJocelyn O. Eidahl
Jocelyn O. Eidahl
NSNizar Y. Saad
Nizar Y. Saad
SHScott Q. Harper
Scott Q. Harper
Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant or digenic disorder linked to derepression of the toxic DUX4 gene in muscle. There is currently no pharmacological treatment. The emergence of DUX4 enabled development of cell and animal models that could be used for basic and translational research. Since DUX4 is toxic, animal model development has been challenging, but progress has been made, revealing that tight regulation of DUX4 expression is critical for creating viable animals that develop myopathy. Here, we report such a model — the tamoxifen-inducible FSHD mouse model called TIC-DUX4. Uninduced animals are viable, born in Mendelian ratios, and overtly indistinguishable from WT animals. Induced animals display significant DUX4-dependent myopathic phenotypes at the molecular, histological, and functional levels. To demonstrate the utility of TIC-DUX4 mice for therapeutic development, we tested a gene therapy approach aimed at improving muscle strength in DUX4-expressing muscles using adeno-associated virus serotype 1.Follistatin (AAV1.Follistatin), a natural myostatin antagonist. This strategy was not designed to modulate DUX4 but could offer a mechanism to improve muscle weakness caused by DUX4-induced damage. AAV1.Follistatin significantly increased TIC-DUX4 muscle mass and strength even in the presence of DUX4 expression, suggesting that myostatin inhibition may be a promising approach to treat FSHD-associated weakness. We conclude that TIC-DUX4 mice are a relevant model to study DUX4 toxicity and, importantly, are useful in therapeutic development studies for FSHD.

1 October 2019 in Molecular Therapy
Verified
Journal Article
Open access
JCJacob T. Cain
Jacob T. Cain
SLShibi Likhite
Shibi Likhite
KWKatherine A. White
Katherine A. White
DTDerek J. Timm
Derek J. Timm
SDSamantha S. Davis
Samantha S. Davis
JWJill M. Weimer
Jill M. Weimer
CLN6-Batten disease, a form of neuronal ceroid lipofuscinosis is a rare lysosomal storage disorder presenting with gradual declines in motor, visual, and cognitive abilities and early death by 12-15 years of age. We developed a self-complementary adeno-associated virus serotype 9 (scAAV9) vector expressing the human CLN6 gene under the control of a chicken β-actin (CB) hybrid promoter. Intrathecal delivery of scAAV9.CB.hCLN6 into the cerebrospinal fluid (CSF) of the lumbar spinal cord of 4-year-old non-human primates was safe, well tolerated, and led to efficient targeting throughout the brain and spinal cord. A single intracerebroventricular (i.c.v.) injection at post-natal day 1 in Cln6 mutant mice delivered scAAV9.CB.CLN6 directly into the CSF, and it prevented or drastically reduced all of the pathological hallmarks of Batten disease. Moreover, there were significant improvements in motor performance, learning and memory deficits, and survival in treated Cln6 mutant mice, extending survival from 15 months of age (untreated) to beyond 21 months of age (treated). Additionally, many parameters were similar to wild-type counterparts throughout the lifespan of the treated mice.

2 November 2014 in RNA Biology
Verified
Journal Article
Open access
QHQing Huo
Qing Huo
MKMelis Kayikci
Melis Kayikci
POPhilipp Odermatt
Philipp Odermatt
KMKathrin Meyer
Kathrin Meyer
OMOlivia Michels
Olivia Michels
DSDaniel Schümperli
Daniel Schümperli
Spinal Muscular Atrophy (SMA) is caused by deletions or mutations in the Survival Motor Neuron 1 (SMN1) gene. The second gene copy, SMN2, produces some, but not enough, functional SMN protein. SMN is essential to assemble small nuclear ribonucleoproteins (snRNPs) that form the spliceosome. However, it is not clear whether SMA is caused by defects in this function that could lead to splicing changes in all tissues, or by the impairment of an additional, less well characterized, but motoneuron-specific SMN function. We addressed the first possibility by exon junction microarray analysis of motoneurons (MNs) isolated by laser capture microdissection from a severe SMA mouse model. This revealed changes in multiple U2-dependent splicing events. Moreover, splicing appeared to be more strongly affected in MNs than in other cells. By testing mutiple genes in a model of progressive SMN depletion in NB2a neuroblastoma cells, we obtained evidence that U2-dependent splicing changes occur earlier than U12-dependent ones. As several of these changes affect genes coding for splicing regulators, this may acerbate the splicing response induced by low SMN levels and induce secondary waves of splicing alterations.

21 July 2023 in Molecular Therapy
Verified
Journal Article
Open access
SPSamantha Powers
Samantha Powers
SLShibi Likhite
Shibi Likhite
KGKamal K. Gadalla
Kamal K. Gadalla
CMCarlos J. Miranda
Carlos J. Miranda
AHAmy J. Huffenberger
Amy J. Huffenberger
KMKathrin Meyer
Kathrin Meyer
The AAV9 gene therapy vector presented in this study is safe in mice and non-human primates and highly efficacious without causing overexpression toxicity, a major challenge for clinical translation of Rett Syndrome gene therapy vectors to date. Our team designed a new truncated methyl CpG binding protein 2 (MeCP2) promoter allowing widespread expression of MeCP2 in mice and non-human primates after a single injection into the cerebrospinal fluid without causing overexpression symptoms up to 18 months post injection. Additionally, this new vector is highly efficacious at lower doses compared to previous constructs as demonstrated in extensive efficacy studies performed by two independent laboratories in two different Rett syndrome mouse models carrying either a knockout or one of the most frequent human mutations of MeCP2. Overall, data from this multicenter study highlights the efficacy and safety of this gene therapy construct, making it a promising candidate for first in human studies to treat Rett syndrome.